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INTRODUCTION 
Atrial fibrillation in general 
Atrial fibrillation is one of the most common irregular heart rhythms. It affects more than 2.2 
million people and more than 160,000 new cases of atrial fibrillation are diagnosed in the 
United States each year. The impulse rate through the atria can range from 300 to 600 beats 
per minute. Fortunately, the atrioventricular node limits the number of impulses that go to the 
ventricles. The resulting heart beat becomes irregular, ranging from about 50 to 150 beats 
per minute1'. In 90% of the cases, atrial fibrillation is secondary to some cardiovascular or 
related chronic disease such as hypertension, coronary artery disease, valve disease, 
chronic lung disease, heart failure, chardiomyopathy, congenital heart disease, a pulmonary 
embolism, hyperthyroidism or pericarditis. It frequently evolves after open chest cardiac 
surgery. In 10% of the cases atrial fibrillation develops as a direct consequence of alcohol 
abuse, excessive caffein use, stress, intoxication from taking illicit drugs, electrolite or 
metabolic imbalances, or severe infection. In some cases there may be no identifiable cause. 
It could be that hereditary channelopathies are responsible for this type of atrial fibrillation of 
obscure origin2. The risk of atrial fibrillation increases with age, especially after sixty3, and is 
clearly dependent on the gender and ethnicity4,5. At present, atrial fibrillation is regarded as a 
dangerous disease. Because in atrial fibrillation the heart beats rapidly and irregularly, blood 
flow through the atria is not satisfactory. This makes the blood more likely to clot. If a clot is 
pumped out of the heart it can travel to the brain, resulting in a stroke6,7. People with atrial 
fibrillation are 5 to 7 times more likely to have a stroke than the average person. A clot can 
also travel to other organs (kidneys, heart, intestines) and damage them. In 20 to 30% of 
cases atrial fibrillation impairs the pumping ability of the heart, precipitating or inducing heart 
failure. Chronic atrial fibrillation is associated with an increased risk of death3. 
Chronic atrial fibrillation is known to be accompanied by many changes both at the 
tissue and cardiomyocyte level. From an electrophysiological point of view the most typical 
changes are those associated with the restitutional properties and form of the action 
potential. Novel pharmacological interventions suitable for long-term medication of the 
disease, as well can not be contrived without a better understanding of the processes behind 
electrophysiological mechanisms. 
The normal atrial action potential 
The "spike-and-dome" shape of the normal human atrial trabecular action potential can be 
characterized by a steep early repolarization (2-5 ms APD20), a low plateau potential (-25 -30 
mV) and a slow late depolarization (300 - 400 ms APD go)8. The speed of the fast 
4 
depolarization (Vmax) of the atrial action potential is comparable to the ventricular action 
potential, and is generally between 190 and 400 v/s9'73,83,85. 
AMP 
FIGURE 1 
The normal human action potenial and its electrophysiological parameters 
The characteristic parameters of atrial action potentials are the same for all excitable tissues. 
They can be characterized by a resting potential (RMP), amplitude of the action potential 
(AMP) and the action potential duration at different repolarization levels (APD10_9o). In order to 
characterize the "spike-and-dome" shape of action potentials, the relative or absolute values 
of notch and plateau amplitudes are used. Taking into account the fact that the shape of 
atrial action potentials may vary considerably owing to the effects of physiological 
pathophysiological processes and drugs, and also that the shape of action potentials and the 
liability of atrial tissue to fibrillate are strongly connected, the proportionality between APD2o 
and APDso ( TRIANGULARITY ) is also a useful parameter10 ( Fig 1 ) for classifying the 
action potential. 
Main ionic currents and their role in electrical activity of the atrial myocardium 
The form of the atrial action potential arises from a complex interplay between different ionic 
currents. Early fast depolarization is brought about by fast Na+ channels11 (lNa), as is the case 
in every excitable tissue. The contraction is triggered by Ca2+ entering the cells through the 
slow Ca2+ channels12 (ICaL). When determining the intracellular Ca2+ contents ([Ca2+]0 of 
intracellular Ca2+ stores other Ca2+ channels are also important. These are the T-type Ca2+ 
channel (ICaT) operating in the resting potential range13, the tetrodotoxine-sensitive Ca2+ 
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channel14 (ICa-rrx)- and as some yet undetermined Ca2+ channels that carry the so-called 
"capacitive" Ca2+ currents15. It is known that there are two extrusion mechanisms for 
removing Ca2+ from the cell. These are the Na+-Ca2+ exchanger16 (NaCaex) which uses the 
electrochemical gradient of Na+ and the sarcolemmal Ca2+ pump17 (SRCapmp). As to what 
extent these two mechanisms are responsible for maintaining normal intracellular Ca2+ 
concentrations under various physiological and pathophysiological conditions is still only 
partially understood. The direction of Na+-Ca2+ exchange varies during the action potential 
phases. At potentials corresponding to the plateau of the action potential Na+ is extruded 
from the cell and Ca2+ is transported into it. The Na+-Ca2+ exchanger reaches its maximal 
activity around the peak of the plateau of the atrial action potential, thereby influencing the 
time course of repolarization18. Early fast repolarization is brought about by a transient 
outward K+ current19,20,21 (lt0) and by the atrium-specific ultrarapid delayed rectifying K+ 
current22, (IKur). 
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FIGURE 2 
Ionic currents and the gene correlates of the pore forming and regulatory subunits in 
the human atrial myocardium23'24,32 
In atrial tabecular muscles, IKur is one of the most important repolarizing currents. Atrial 
tabecular muscle contains conventional slow and fast K+ channels similar to other myocardial 
muscles that can be activated with normal action potential configurations, as well. The most 
important of them are the rapid and slow delayed rectifier K+ currents ( IKS and Ikv ), which 
become activated during the action potential plateau25,26. If a repolarization level of 50-60 % 
is exceeded the inward rectifier K+ channel ( If^ ) is activated and the outward current flowing 
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through this channel further assists the membrane to return to the resting potential27,28. The 
activity of inward rectifier K+ channels are not important in overshooting or in the plateau 
domain of the action potentials. The shift in ionic concentrations through action potentials are 
restored by the Na+-K+ pump (INaKpmp). The pump is electrogenic and takes part in the final 
shaping of the action potentials29. Atrial tissue contains other ionic channels too, the two 
most important being the acethycholine-sensitive ( IKAch ) and ATP-sensitive K+ channels ( 
IKATP )30,31- During the plateau phase a sustained outward current is also activated ( lp ). 
However, this macroscopic current is the result of more than one primary channel function 
with different kinetics and varying ion-specificity32. In the tissue of the right atrium under 
normal physiological conditions a channel responsible for the pacemaker current ( If) can 
also be observed33. The membrane density of this channel is not yet known. To complicate 
the picture it should be noted that the presence of ionic channels or channel proteins does 
not necessarily mean that these channels are functional. Most likely each channel can be 
coupled to one or more regulatory protein. A given regulatory protein can modify the 
behaviour of more ionic channels. Ionic channels can be coupled to structural proteins 
available intra- or extracellularly, which can also modify their kinetic parameters32 ( Fig 2 ). In 
theory one could conceive of a situation where the results of measurements of currents may 
be the same although the detailed composition of channels and regulatory proteins are quite 
different. The variation of the channel composition and the up- and down-regulation of some 
channels can produce significant changes in the shape of the action potentials (electrical 
remodelling) and, as a consequence, changes in the restitution parameters of the action 
potentials. The unfavourable changes of the restitution parameters of the action potentials 
are considered today to be the most important factors in the onset and continuation of atrial 
fibrillation34,35,36. 
Electrical remodelling and its importance in the perpetuation of atrial fibrillation 
The elevated atrial frequency may be a consequence of automacy or reentry which 
eventually leads to the perpetuation of atrial tachycardy, to atrial flutter and to chronic atrial 
fibrillation37,38. It seems that the regularity and organization of electrical activity, by following 
the tachycardy-atrial flutter-atrial fibrillation sequence39, gradually shifts from temporally 
organized patterns (sinus-rhythm and tachycardy) to spatially-organized patterns (atrial flutter 
and chronic atrial fibrillation). The key characteristic of atrial fibrillation is the appearance of 
spatial independence and multiplication of time scales40. Whatever the reason for it the 
consequence of rhythm enhancement will undoubtedly be a steady increase in intracellular 
Ca2* concentrations17,18,41,42 ( Fig 3 ). 
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FIGURE 3 
More frequent activation of atrial myocytes leads to an increase in the overall 
intracellular Ca2+ concentration 
Alongside these changes, the atrial action potential becomes triangular in form and the 
mechanical activity gets reduced. It is well known that in fibrillating human myocardium the 
density of L-type Ca2+ channels is low. Data on the alterations of density of fast Na+ channels 
are contradictory. In fibrillating atrial myocardium the density of transient outward K+ 
channels is also low. The densities of the IKAch and IKATP channels, as well as the amount of 
calsequestrin in the sarcoplasmic reticulum are down-regulated too. However, the lf density 
in the sarcolemma and number of IP3-sensitive Ca2+-release receptors in intracellular 
reticular membranes are upregulated. The densities of other repolarizing K* channels are 
also altered by chronic atrial fibrillation. Moreover IKur, IKS and IKr are unchanged or down-
regulated, while IKT is either elevated or decreased41,43 ( Fig 4 ). 
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FIGURE 4 
Changes in densities of ionic channels and Ca2+ handling proteins and the consequences 
on the electrical and mechanical activity in chronic atrial fibrillation 
Combining the results of experiments on human preparations and animal fibrillation models, 
what seems to be an overall response of the mammalian myocardium to the atrial fibrillation 
is the down-regulation of Ca2+ channels together with that of repolarizing K+ currents 
operating in voltage domains of these Ca2+-channels44 ( Fig 5 ). It is worth noting, that there 
is no perfect experimental model for atrial fibrillation. This is partly because distinct species 
expressing though similar channel composition may utilize considerably different 
mechanisms to minimize detrimental cellular effects of the atrial fibrillation. Diverse changes 
in the IKS, IKr and IKT densities may reflect the fact that "sterile" atrial fibrillation in humans is 
relatively rare and atrial fibrillation is more often a consequence of other disorders45-46. To 
make a precise distinction between original and secondary processes in this respect is still 
quite impossible. 
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FIGURE 5 
Remodelling in human atrial fibrillation and animal fibrillation models 
Diversity of the trabecular action potential forms 
Our results obtained from analyzing the incidence of the different action potential forms in 
isolated right atrial preparations from "healthy" subjects or from patients with atrial fibrillation 
also highlight the importance of other pathological processes which may trigger the disease. 
The frequency of triangular action potential forms was 24% in atrial trabeculae from "non-
fibrillating" patients. In atrial fibrillation the triangular action potential form is thought to be 
unexceptionally common. In our current experiments, however, the typical triangular shape 
was characteristic only in 69% of diseased patients ( Fig 6 ). This means that atrial fibrillation 
induces remodelling (i.e changes in densities of ionic channels and in the shape of the atrial 
action potentials), but remodelling can occur for other reasons too45,46. In the latter case atrial 
fibrillation is a consequence rather than a cause. The seemingly attractive statement "atrial 
fibrillation begets atrial fibrillation"47 should perhaps be amended to "remodelling begets atrial 
fibrillation - and vice versa - atrial fibrillation begets remodelling". No doubt the mechanism 
for atrial fibrillation is a circulus vitiosus which has two entry points. 
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FIGURE 6 
The occurence of fibrillating (triangular) action potential forms in human right atrial 
trabeculae obtained from patients either with sinus-rhythm ( SR ) or with diagnosed 
atrial fibrillation ( AF ) 
Many medications for the treatment of atrial fibrillation are available at present48,49,50. These 
drugs include quinidine, procainamide, disopyramine, propafenone, flecainide, sotalol51, 
dofetilide, ibutilide52, tedisamil, azimilide53,54 and amiodarone55,56 (Classl and 3 
antiarrhythmics according to Vaughan-Williams57,58,59), beta-blockers such as carvediol or 
propranolol (Class 2) and non-dihydropyridine Ca-antagonists like verapamil60,61 or 
diltiazem62 (Class 4) or digoxin. The principal drawback about them all is that they are not 
organ specific enough (they also influence the ventricular functions). Their effectiveness is 
unsatisfactory in practice (they are effective only in 30-60% of the cases and this 
effectiveness may even decrease with time; most drugs have a 70% failure rate after one 
year) and many of them possess potentially serious side effects. Over the past decade 
various studies have demonstrated that long-lasting preventive administrations of Classl 
antiarrhythmics should be avoided in patients who had heart failure, cardiac ischaemia or a 
previous myocardial infarction because of the enhanced propensity of proarrhythmia63, which 
may increase the mortality rate. Pure Class 3 drugs like sotalol64, ibutilide and dofetilide also 
Problems with drugs presently used in the treatment of atrial fibrillation 
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share this proarrhythmic feature; they show a high rate of incidence of torsade de pointes 
(reported values in studies vary from 1 to 4.8% for the Class 3 antiarrhythmics and from 2 to 
8.8% for quinidine)65. 
IKM, as a potential target in the treatment of atrial fibrillation 
The discovery of IKur in the early 90s66,67 gave a new impetus to the development of atrial 
specific antiarrhythmics. It was shown that this channel could selectively be blocked by 
micromolar 4-aminopyridine (4-AP) concentrations26,68. Although earlier experiments on the 
4-AP effects in multicellular preparations could not demonstrate unambigous APD 
lengthening69,70 ( a noticeable sign of antiarrhythmic action of selective K+ channel blockers 
), leading researchers have since begun to hold the view that 4-AP does indeed prolong the 
APD in both healthy and remodelled atrial myocytes71 and the application of 4-AP or similar 
compounds should be the breakthrough in the treatment or prevention of atrial fibrillation of 
any type. 
AIM OF THE PRESENT STUDY 
The aim of the present study was to examine whether the effects of the 4-AP caused an IKur 
block on the action potential parameters in right atrial preparations obtained from healthy 
individuals and also from patients with chronic atrial fibrillation going back 3 months or more. 
Keeping in mind, that a preponderant number of the subjects get the first incidence of atrial 
fibrillation at the predominance of the parasympathetic tone, 4-AP experiments with complete 
muscarinergic (M2) receptor activation were also considered. The action potential restitution 
and modification by antiarrithmics is known to play a crucial role both in the pathomechanism 
and the antiarrhythmic therapy of rhythm disturbances. Hence we also intended to 
characterize 4-AP effects on the action potential restitution in atrial preparations of either 
type ( i.e. "healthy" or "sinus-rhythm" and "fibrillating"). In order to verify the 4-AP-induced 
action potential effects and also to explore the IKur block-induced secondary changes in 
other important current entities of the atrial myocardium, we intended to develop an action 
potential model. It was also considered that, by revealing the exact interplay of ionic currents 
during the atrial action potential, new antiarrhythmic approaches might also be suggested. 
The mechanism of action of 4-AP was also compared with those of lidocaine, detajmium83 
and tedisamil72 8S. 
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METHODS 
Human atrial preparations 
Right atrial appendages were obtained from 49 patients with sinus-rhythm and 16 patients 
with chronic atrial fibrillation. There was a slight differences in sex, underlying heart disease 
and left atrial diameter between the two groups. Patients with atrial fibrillation were more 
frequently medicated with digitalis, Ca-antagonists of non-dyhydropyridine type and nitrates 
than sinus rhythm patients. However, verifying the differences statistically proved impossible 
in practice because of the low number of cases. The existence of such differences is well 
known and has also been demonstrated by us in other experiments73. 
Other types of cardiac preparations 
In experiments for analyzing the effects of drugs on cardiac action potentials of other 
species, canine and rabbit preparations were also used. The concerning methodological 
details are published elsewhere83,85,87. 
Action potential recordings 
About 25 min after the appendages had been removed the atrial trabecuiae were prepared. 
Then the trabecuiae were mounted onto the bottom of an organ bath perfused with 
oxigenated Tyrode's solution having a molar composition like that published elsewhere73,87. 
Before starting an experiment, the preparations were left to stabilize for 40 min. During this 
adaptation period and also throughout the whole experiment, the preparations were 
subjected to rectangular pulse stimuli at a driving rate of 1Hz. Transmebrane potentials were 
recorded via microelectrode impalement. When the preparations failed to function and action 
potentials could not be evoked even when exceptionally high stimulus intensities were 
applied, 1 pM carbachol was added to the bath. If the electrical activity was restored and 
carbachol could be removed without worsening of the transmebrane potential parameters ( 
i.e. changes remained within 1% for 10 min after a 30 min long washout) the preparations 
were regarded as normal. Otherwise they were rejected. 
Action potential restitution 
The action potential restitution was established by using extra impulses at 1Hz basic cycle 
length. Extra impulses were delivered to the preparation after every tenth regular beat. The 
coupling time of extra impulses was altematedly varied in a 3000 ms range following the 
effective refractory period. 
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Transmembrane potential parameters followed 
In addition to the usual parameters ( the resting potential: RMP, action potential amplitude: 
AMP, maximum rate of depolarization: Vmax, action potential durations at different percentage 
values of repolarization: APDX) parameters for the the action potential notch ( NOTCH ) and 
the action potential plateau ( PLATEAU ) were introduced. The action potential form was 
characterized by a triangularity parameter ( TRIANGULARITY ) calculated as the natural 
logarithm of the weighted APD2o/APD80 ratio. ( Fig 1 ) Numeric values of the relevant 
parameters were obtained automatically from signals obtained via a program written by the 
author83,87. 
Drugs applied in this study 
In the present work, detajmium, tedisamil, 4-aminopyridine (4-AP), carbachol and E-4031 
were used. Small amounts of stock solutions were added directly to the organ bath. 
Concentration-response relationships were determined by applying (4-AP) cumulatively. In 
the case of E-4031, the solvent was dimethyl-sulfoxide (DMSO). To exclude unwanted 
solvent effects, single experiments were also carried out solely with DMSO. In these 
experiments DMSO did not alter the transmebrane potential when its volume-concentration 
remained below 0.2%. This DMSO concentration was never exceeded in our experiments. 
Incubation with each set 4-AP concentration lasted for 20-40 min. Lidocaine and carbachol 
effects were left to evolve for 15-30 min. The exposure to detajmium, tedisamil or E-4031 
lasted for 30-50 min. 
Statistical analysis 
Drug effects were statistically verified with Student's t test for paired observations. In the 
case of the restitution curves one-way ANOVA and Bonferroni post tests were used for 
statistical evaluations. The results with E-4031 were statistically analyzed with one-way 
ANOVA and Dunn's test. The diversity of action potential forms in sinus rhythm and atrial 
fibrillation was statistically verified by applying the G-test. All the data obtained 
experimentally are expressed as means ±SE. Changes were regarded as significant when 
p<0.05. 
Computer simulation 
The human atrial action potential model was based on the research work of 
others71-74-75-76-77-78-79-80-81. It was written in the PASCAL language and was run in DOS mode 
on an 800 MHz IBM-clone PC with Pentium II processor. The maximum conductance values 
of ionic currents were taken from the literature. In order to get realistic action atrial potential 
forms most of them had to be readjusted. For numerical integration of the mebrane potential 
change caused by the instantaneous transmembrane currents a modified Euler-method was 
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applied s. Depending on the estimated error, the integration step was varied automatically 
between 0.001 and 1ms. Before recording a simulated action potential, ionic concentrations 
in different compartments were left to stabilize for 200 cycles. ( APPENDIX: Fig 23, TABLE 
6-8 ). All simulations had a steady-state driving rate of 1Hz82. 
RESULTS 
4-aminopyridine concentration-respons curves at 1Hz rate in SR-preparations 
In "healthy" atrial appendage preparations stimulated at a driving rate of 1Hz, 4-AP induced 
concentration dependent changes in action potential parameters, especially in those for the 
plateau phase and action potential durations at repolarization levels below 50%. Increasing 
4-AP concentrations ranging from 0.3 to 100 pM elevated the height of the action potential 
plateau ( control: -22.6 ±0.8 mV, 100pM 4AP: -2.8 ±1.9 mV, n=5 ) with an EC50 of 13pM. 
Besides the plateau elevation, the notch potential was moved to more positive values ( 
control: -26.1 ±1.2 mV, 100 pM 4AP: -6.3 ±1.1 mV, EC50: 16 pM ) and the APD90 value was 
shortened ( control: 293.7±15.1 ms, 100pM 4AP: 243.2±11.8 ms, EC50: 7.3pM ). Even when 
100 pM or higher 4-AP concentrations have been applied, the effects could always be 
reversed in 30 min after the removal of the drug. ( Fig 7 ). The lowest 4-AP concentrations 
inducing statistically verifiable plateau elevation seemed to be between 3 and 10 pM. 
A max (plateau) 
" m i n ( n o t c t 1 ) 
—i—1 1—i 1 1 1 1 1 1— 
c - 7 - 6 - 5 - 4 - 3 -2 -1 
log [4-AP, M ] 
FIGURE 7 
Human right atrial action potentials as affected by increasing 4-aminopyridine 
concentrations at 1 Hz steady-state driving rate 
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The effects of low 4-aminopyridine concentrations on the action potential parameters 
in right atrial trabecules obtained from patients with sinus rhythm 
5pM of 4-AP significantly elevated the notch and plateau potentials from -31.7 ±4 to -21.8 
±4.8 and from -21.0 ±2.5 to -6.5 ±2.5 mV ( n=16 ). At the same time, the APD80 and APDgo 
values were significantly shortened by 9 and 15% respectively ( APD80: 290.8 ±6.2 vs. 264 
±8.0 ms [p < 0.010] and APD90: 413.6 ±10.4 vs. 350.0 ±10.1 ms [p < 0.001]). Vmax, the action 
potential amplitude and APDs below 20% of repolarization did not change significantly. In the 
presence of 5 pM of 4-AP the sinus rhythm action potentials became noticeably more 
triangular ( TABLE 1, Fig 8A ). 
Effect of 5-pM 4-amin 
in human righ: 
opyridine on t 
atrial appenc 
TABLE 1 
he action potential parameters at a drivin 
ages obtained from patients with sinus-r 
g rate of 1 Hz 
hythm 
RMP 
(mV) 
AMP 
(mV) 
vmax 
(V/s) 
APD20 
( ms ) 
APD80 
( ms ) 
APD90 
(ms) 
NOTCH 
(mV) 
PLATEAU 
(mV) TRIANGULARITY 
abs amp abs amp 
control -75.2 
±0.8 
100.9 
±2.1 
280.7 
±15.7 
4.9 
±1.6 
290.8 
±6.2 
413.6 
±10.4 
-31.7 
±4.0 
43.5 
±4.3 
-21.0 
±2.5 
54.2 
±2.9 
-3.2 
±0.22 
+ 5UM 
4-AP 
-74.4 
±1.0 A 
100.0 
±2.3 
267.3 
±15.7 
12.1 
±4.8 • 
264.1 
±8.0 • 
350.0 
±10.1 • 
-21.8 
±4.8 • 
52.7 
±5.3 • 
-6.4 
±2.5 • 
68.0 
±3.1 • 
-2.4 
±0.31 • 
mens±SE, n = 15, p< 0.05, abs: absolute values, amp: amplitude from RMP 
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FIGURE 8 
Human right atrial action potentials in sinus rhythm ( A ) and atrial fibrillation ( B ) as 
affected by 5 pM of 4-aminopyridine at a steady-state driving rate of 1Hz 
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The effects of 4-aminopyridine concentrations in atrial fibrillation 
In trabeculae taken from patients with chronic atrial fibrillation, the action potential plateau 
runs routinely above 0 mV and the notch potential can not clearly be defined or its position in 
repolarization can vary quite considerably. 5 pM of 4-AP was able to further elevate this 
increased fibrillating action potential plateau by 15% ( control: 0.36 ±3.3 mV, 4-AP: 12.4 ±2.5 
mV; n =6 [ p< 0.01 ]). The increase in the notch amplitude caused by the drug was also 
detectable but its true extent may be somewhat overestimated because the determination of 
this parameter is imprecise with highly triangular action potential forms. In contrast with 
sinus-rhythm preparations, the APD80 and APD90 values were lengthened by 5pM of 4-AP in 
"fibrillating" trabeculae (from 233.8 ±12.0 to 258.5 ±10.9 ms [p<0.01] and from 300.4 ±16.3 
to 320.2 ±13.3 ms [p<0.01], respectively ). The numerical value of the 4-AP-induced increase 
in the APD2o value ( 123% ) could be solely attributed to drug-effects on the height of the 
action potential plateau. Neither Vm3x nor the resting potential and action potential amplitude 
were changed by 5 pM 4-AP in tabeculae from patients with atrial fibrillation. ( Fig 8B, 
TABLE 2 ) 
TABLE 2 
Effect of 5-pM 4-aminopyridine on the action potential parameters 
in human right atrial appendages obtained from patients with chronic atrial fibrillation 
at driving rate of 1Hz 
RMP 
( M V ) 
AMP 
( M V ) 
VMAX 
( V / S ) 
A P D 2 0 
( M S ) 
APDso 
( M S ) 
APD90 
(ms) 
NOTCH 
(mV) 
PLATEAU 
(mV) TRIANGULARITY 
abs amp abs amp 
control -79.7 106.5 291.0 34.8 233.8 300.4 -52.8 26.8 0.4 80.0 -0.71 
±2.7 ±3.4 ±28.2 ±8.6 ±12.0 ±16.3 ±11.9 ±12.0 ±3.3 ±2.4 ±0.28 
+ 5pM -79.3 106.8 291.6 77.7 258.5 320.2 -23.9 55.4 12.4 91.8 0.18 
4-AP ±2.6 ±2.3 ±20.3 ±5.0 ±10.9 ±13.3 ±15.1 ±15.8 ±2.5 ±1.6 ±0.05 
• • • • • • • • 
mens±SE, n = 6, ~k: p < 0.05, abs: absolute values, amp: amplitude from RMP 
Changes in ionic currents secondary to the selective IK,^ inhibition in sinus rhythm 
and atrial fibrillation as revealed by the action potential simulation 
The shape and potential domain of the "healthy" right atrial action potential plateau were 
dependent on the activity of the ICaL, IKur and IKr currents. The intensity of lt0 reaches its 
highest value (4.8pA/pF) at 3.1 ms after the onset of the action potential and thereafter 
decreased quite rapidly. At the time associated with the action potential notch, the intensity of 
I to was still 0.45 pA/pF. At the climax of the action potential dome (i.e. at 72.5 ms), though, 
practically no current passed through this type of K+ channel. The IKur current becomes 
activated with kinetics comparable to that of lt0, but its inactivation process is absent (or to be 
more precise it is negligibly slow ). Consequently, during most of the repolarization phase, 
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IKur acts rather like a simple voltage-dependent current. As the repolarization process 
proceeds, IKur becomes gradually deactivated and at voltages below -55 mV the IK^ current 
no longer flows. In our action potential simulations this voltage limit was reached at APDs 
longer than 175 ms. Owing to the rapid voltage drop during the fast repolarization phase of 
the action potential, the evolution of the IKr activation slackens. In sinus-rhythm, the IKr 
intensity reaches its maximum ( 0.8 pA/pF ) at 121 ms, that is by 43 ms after the top of the 
dome. During the late repolarization of the action potential, IKr activity gradually diminishes. 
IKS gets activated more slowly and at a more positive voltage than IKr. This more positive 
activation voltages can not be reached in case of sinus rhythm action potentials. However, 
the IKS activity might be positively regulated not only by the membrane voltage but also by 
[ C a 2 + ] j . Depolarized voltages insufficient for activating IKS alone and increasing intracellular 
[Ca2+]i together do activate IKS even in normal sinus-rhythm action potentials (provided that 
IKS is expressed at a reasonably high density in human atrial myocytes). In our simulations, 
the maximum IKS activity was 0.23 pA/pF and reached its peak after 127 ms. Under control 
conditions, the time course of ICaL is biphasic with a small transient peak at 10 ms with a 
slower evolving but greater secondary current ampitude (-3.2 pA/pF) at 68 ms. This biphasic 
Ca2+ entry through ICaL makes the intracellular Ca2+ transient slightly biphasic, as well. The 
Ca2+ transient increases relatively fast and reaches a 23 ms long plateau with a [Ca2*]; of 1.2 
pM. During the action potential dome phase, the Ca2+ transient increases further until a 
maximum of 1.5 pM at 71 ms is reached. [Ca2+]i then returns to its normal systolic level ( 0.2 
pM ). In our action potential model the Ca2+ transient persists 150-200 ms longer then the 
action potential. ( Fig 9A). 
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FIGURE 9 
The effects of IKur inhibition on other ionic currents and on the [Ca2+]j transient 
in "healthy" human atrial myocytes ( computer simulation ) 
The sarcolemmal Ca2+ pump was not incorporated in our model, the removal of the surplus 
myoplasmic [Ca2+] resides solely in activities of the Na+-Ca2+ exchange and the reticular Ca2+ 
pump. Ignoring the very top of the atrial action potential, the exchanger current flows inwardly 
with a maximum of-4.4 pA/pF at 200 ms. When IKur is blocked, inward currents through ICaL 
and INaCaEx become unbalanced and notch and plateau potentials get more depolarized. 
The more positive the plateau and notch potentials are, the more IKr gets activated and ICaL 
and INaCaex currrents become couterbalanced again. In this way a 90% inhibition of IKur 
causes an 80% increase in IKr activity. This more intense IKr repolarizes the membrane more 
effectively and the resulting APD90 value becomes even shorter than it was with unblocked 
IKur (in simulation: 220 ms vs. 260 ms as control). An equally significant increase in IKS 
activity secondary to a 90% IKur block was not be seen. Both L-type Ca2+ current and the 
amplitude and time-integral of the Ca2+ transient get, however, markedly increased ( by 35 
and 12 and 13 %, respectively ). Owing to the changes in current activities and Ca2+ flows, 
the maximum dome potential is reached earlier too (51 vs. 69 ms as control). ( Fig 9B, Fig10 
)• 
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FIGURE 10 
The effect of selective inhibition of IKur on the action potential in sinus-rhythm and 
atrial fibrillation at a steady-state stimulation of 1Hz ( computer simulation ) 
In the the model for fibrillating atrial myocyte reduced lt0, IKur, IKS, IKr and ICaL currents were 
incorporated with maximum conductances values of 0.01, 0.003, 0.2, 0.025 and 0.005 
mS/pF, respectively (APPENDIX, TABLE 7). This resulted in a realistic "fibrillating" action 
potential form with 21 ms APD2o, 155 ms APD90 and an average plateau level of -9.5 mV. 
Here a 90% inhibition of IKur also brought about a 3% increase in the amplitude of L-type 
Ca2+ current, a 22% enhancement of the [Ca2+ I transient, and also forced the Na+-Ca2+ 
exchange to carry more inward current. These effects tended to make the APD longer. The 
increase in IKr activity, resulting from the IKur block-induced depolarization of the action 
potential plateau from -9.5 to -2.8 mV, was 53%. This augmentation, however, was 
insufficient to neutralize the increase in intensity of inward currents so a net APD 
prolongation appeared. When "fibrillating" action potentials with reduced IKur activity were 
simulated, APD20 and APD90 values rose by 98% and 6%, respectively ( Fig 9B, Fig 10 ). 
As the results obtained with our human action potential model revealed, the APD 
effects of an IKur block may be strongly modulated by the activity of other delayed rectifiers, 
especially by the IKr one. 
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Modulation of 4-aminopyridine effects by restraining the IKr activity 
In a sinus rhythm preparation, the selective IKr blocker E-4031 though seemed to increase 
APD80 and APD90 values, but the changes did not prove to be significant ( 281.0 ±37.7 ms 
APD80 and 412.1 ±42.8 ms APD90 in the presence of 1pM E-4031 vs. APD80 and APD90 
values of 252.2 ±27.5 and 362.3 ±29.5 ms as controls, respectively; n = 5 ). 
TABLE 3 
The effect of E-4031 on the 4-aminopyridine-induced action potential changes 
at a driving rate of 1Hz in human right atrial appendages obtained from patients 
with sinus-rhythm 
RMP 
( m V ) 
AMP 
( m V ) 
VMAX 
( V / s ) 
APD20 
( m s ) 
APD80 
( m s ) 
APDGO 
( m s ) 
NOTCH 
( m V ) 
PLATEAU 
( m V ) TRIANGULARITY 
abs amp abs amp 
control -72.4 
±1.1 
97.3 
±3.3 
280.4 
±30.2 
2.1 
±0.5 
252.2 
±27.5 
362.3 
±29.5 
-29.8 
±1.7 
42.6 
±2.6 
-26.5 
±1.8 
45.8 
±2.3 
-3.47 
±0.22 
+1 p M 
E-4031 
-73.3 
±2.1 
96.5 
±3.9 
276.5 
±27.1 
1.9 
±0.3 
281.0 
±37.7 
412.1 
±42.8 
-30.7 
±1.4 
42.6 
±2.7 
-28.7 
±1.5 
44.7 
±3.1 
-3.63 
±0.20 
+ 5 p M 
4-AP 
-72.1 
±1.6 
90.9 
±6.1 
235.5 
±36.7 • 
4.0 
±1.4 
§ 
358.5 
±28.8 • 
483.4 
±32.6 • 
-18.9 
±3.4 
§ 
53.2 
±3.2 
§ 
-14.4 
±2.7 
§ 
57.7 
±2.9 
§ 
-2.83 
±0.78 
§ 
mens±SE, n = 5, §: p < 0.05, E-4031 vs. 4-AP; p < 0.05, control vs. E-4031+4-AP, abs: absolute values, 
amp: amplitude from RMP. Statistical analysis: ANOVA, Dunn's multiple comparison test. 
Still, the application of 5pM 4-AP in the presence of E-4031 resulted in significant APD 
lengthenings both at 80 and 90% repolarization levels, when compared to controls ( APDSo 
was increased to 358.5 ±28.8 and APD90 to 483.4 ±32.6 ms, [p < 0.01]). In the presence of 
E-4031 alone, there was no significant change on the APD2o value. Although having been 
equilibrated with 1 pM E-4031 for 30 min, E-4031-induced changes in notch or plateau 
potentials were not observed. However, both of them became more depolarized when 5 pM 
4-AP was also applied in the presence of E-4031 ( -18.9 ±3.4 and -14.4 ±2.7 mV vs. -30.7 
±1.4 [ p<0.01] and -28.7 ±1.5 mV [p<0.05] notch and plateau potentials for E-4031+4-AP and 
for E-4031 alone, respectively ). In the presence of E-4031 4-AP legthened APD2o as well 
(control: 2.1 ±0.5 vs. E-4031 +4-AP: 4.0 ±1.4 ms [p< 0.05]) ( TABLE 3, Fig 11 ). 
The influence of IKr and IK; intensities on 4-aminopyridine effects as revealed by the 
action potential simulation 
In action potential simulations, the effects of IKur blocking on the APD were dependent on the 
intensities of the IKr and IKS currents. A 75% reduction in IKr conductance resulted in 
simulated action potentials with an APD90 of 313 ms in steady-state. When, in addition, IKur 
was reduced by 90% the action potential plateau was elevated from -14.5 to 2.3 mV. 
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1001TB 
FIGURE 11 
The effect of selective IKur inhibition on the action potential under control conditions 
(A,B) and after IKr had been blocked by lpM E-4031 (C) in "healthy" human right 
atrial myocardium at a steady-state driving rate of 1Hz 
The duration of simulated "sinus-rhythm" action potentials with weak IKr, however, did not 
become shorter after reducing the IKur conductance by 90%. ( control APD90: 315 ms vs. 
APD9o with blocked IKur: 320 ms ). 
Under control conditions (i.e. with strong IKr) simulated "sinus-rhythm" action potential 
forms proved to be insensitive to changes in the IKS intensity (a 50% reduction in maximum 
IKS conductance produced no noticeable change in APD). However, the additional IKur block 
always resulted in APD prolongations in simulations with reduced IKr and IKS intensities. In 
such cases a 90% reduction in maximum IKur conductance lengthened the APDgo from 325 to 
358 ms. 
In the presence of reduced delayed rectifier intensities, the additional IKur block 
elevated the voltage and prolonged the duration of the action potential plateau (-15.4 mV and 
125 ms with blocked IKr vs. -3.0 mV and 158 ms with blocked IKur, and -16.3 mV and 146 ms 
with blocked IKS vs. -2.3 mV and 187 ms with blocked IKS+ IKur).( Fig 12 ) 
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FIGURE 12 
In "healthy" atrial myocytes with weak delayed rectifier currents (IKr and IKS) 
4-AP-induced IKur block does not shorten the action potential duration 
(computer simulation ) 
Effect of IK,,;- blocking on "sinus-rhythm" action potentials in the presence of carbachol 
The pretreatment of sinus rhythm preparations with 1 pM carbachol shortened the action 
potential duration ( 175.4 ±10 and 276.7 ±20.8 ms [n=6] vs. untreated 290.8 +S.3 and 413.6 
± 1 0 . 4 ms [n=16], A P D 8 0 and A P D 9 0 , respectively ), shifted the plateau to more negative 
potentials (-28.4 ±5.8 [n=6] vs. untreated -21.0 ±2.5 mV [n=16]) and slightly hyperpolarized 
the resting mebrane potential (-75.0 ±1.1 [n=6] vs. untreated -72.4 ±1.1 mV [n=16] ). In the 
presence of carbachol, 4-AP elevated the action potential plateau (from -28.4 ±5.8 to -10.6 
±5.5 mV, [n=6], p< 0.01), as was routinelly observed in other preparations too. However, the 
APD 8 O and A P D 9 0 were somewhat lengthened ( from 175.4 ±10.0 and 267 ±20.8 to 240.4 
±16.1 and 330.8 ±26.8 ms, respectively ) by 4-AP after carbachol pretreatment. Other action 
potential parameters measured in the presence of carbachol remained practically unchanged 
by an additional 20 min incubation with 4-AP. ( Fig 13, TABLE 4 ) 
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FIGURE 13 
Effect of 4-AP on the action potential in sinus-rhythm (SR) and atrial fibrillation (AF) in 
two representative preparations in the presence of 1 pM carbachol 
TABLE 4 
Effect of 5-pM 4-aminopyridine 
on the action potential parameters in "healthy" human right atrial appendages 
pretreated with 1 pM carbachol at a driving rate of 1Hz 
RMP 
(mV) 
AMP 
(mV) 
Vmax 
(Wis) 
APD20 
(ms) 
APDso 
(ms) 
APDgo 
( ms) 
NOTCH 
(mV) 
PLATEAU 
(mV) TRIANGULARITY 
abs amp abs amp 
control -75.0 94.2 236.3 7.7 175.4 276.7 -42.8 32.2 -28.4 46.8 -2.36 
±1.1 ±2.1 ±23.4 ±4.5 ±10.0 ±20.8 ±3.6 ±4.1 ±5.8 ±4.8 ±0.43 
+ 5PM -73.1 93.6 236.1 20.00 240.4 330.8 -20.6 52.5 -10.60 62.5 -1.97 
4-AP ±1.4 ±2.1 ±17.8 ±11.1 • ±16.1 • ±26.8 ±8.9 ±8.2 ±5.6 • ±6.0 • ±0.65 
mens±SE, n = 6, p < 0.05, abs: absolute values, amp: amplitude from RMP 
Effect of IKnr blocking on "fibrillatinq" (AF) action potentials in the presence of 
carbachol 
In atrial trabecular preparations taken from patients with chronic atrial fibrillation the action 
potential form varied greatly. The treatment of preparations with 1 pM carbachol did not 
result in any significant APD shortening or in any dramatic change in the characteristics of 
the plateau phase. Exposure of carbachol treated AF trabeculae (n=4) to 4-AP resulted in 
plateau elevation (from -5.8 ±2.3 to +7.5 ±2.9 mV) without any statistically verifiable change 
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in APDgo values (263 ±15.1 ms as control vs. 272 ±16.7 ms after 20 min incubation with 5 pM 
carbachol) ( Fig 13 ). 
Simulation of the effect of I KM, blocking on different ionic currents in the presence of 
activated IKAQ in "healthy" atrial myocytes 
The incorporation of an lKAch current with 0.07 mS/pF in the atrial action potential model 
markedly shortens the action potential duration (from 260 to 149 ms at 90% repolarization) 
shifts the plateau to more negative potentials (from -14.8 to -32.1 mV ) and hyperpolarizes 
the resting potential by 3 mV. The hyperpolarization of the action potential is strong enough 
to make the Ca2+ current weaker during the plateau (maximum current: -2.44 vs. -3.15 pA/pF 
without IKACh )- The lower depolarizing activity arising from this secondary decrease in the 
Ca2+ current intensity is not capable of keeping back the unbroken evolution of the 
repolarization and hence neither the notch nor action potential dome can be formed so the 
restoration of the resting potential can be achieved earlier. Moreover, the faster 
repolarization without an action potential dome weakens the maximum IKr and IKs activities 
too (from 0.8 to 0.2 and from 0.13 to 0.04 pA/pF, respectively). Under such circumstances, 
although only small IKur current flows during the plateau, its role is very important. When IKur 
is blocked the speed of the early repolarization slows down. This slower, early repolarization 
makes ICaL more intensive, and this secondary activated ICaL can even reverse the direction 
of the repolarization for a while, especially after the lt0 has already been inactivated. The 
process results in the formation of a characteristic notch. The upward bending dome makes 
it possible for more IK, to be activated. And this more intense IKr then repolarizes the 
mebrane potential to a level, where the resting potential can be restored by the inward 
rectifiers alone. With activated IKAQ, and unblocked IKur, the Ca2+ influx into the myoplasm 
decreases, which results in a smaller Ca2+ transient, as well. The smaller Ca2+ transient 
brings about a reduction in the rate of the Na+-Ca2+ exchange. The shortening of the APD 
after IKACh activation can also be attributed to this accompanying reduction in the exchanger 
activity. When the IKur is switched off, the Ca2+ transient becomes greater, and the more 
intensive Ca2+ current together with an enhanced inward exchanger current will make APD 
longer. When a high density of IKS is supposed and the IKS is regarded as activated by [ Ca2+ 
]i, the elevated myoplasmic Ca2+ concentration and the more positive plateau potential 
resulting from the IKur inhibition, may theoretically also activate more IKS. However, even it is 
so, the Ca2+-induced recruitment of additional IKS activities remains insufficient in the 
substitution of the absent IKur functions for keeping the action potential duration short ( Fig 
14,15). 
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FIGURE 14 
Effect of IKUr-inhibition on different current activities 
and on the time course of the [Ca2+] transient in the presence of activated IKAch 
(computer simulation ) 
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FIGURE 15 
In human right atrial action potential models with activated IKAch5 IKur inhibition 
lengthens the action potential duration 
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The effect of 4-aminopyridine on the APD-restitution in the presence and absence of 
carbachol in sinus rhythm, atrial fibrillation and at 1Hz driving rate 
As a tendency, the 4-AP induced restitutional APD changes both in sinus-rhythm and 
"fibrillating" atrial tissue could be compared with those determined at a 1Hz driving rate. 
Namely, after 20 min incubation with 4-AP, the APD was shorter practically over the whole 
diastolic interval (Dl) range in sinus-rhythm. However, in "fibrillating" trabeculae or in sinus-
rhythm trabeculae pretreated with carbachol, where APD80 and APD90 values were increased 
with the application of 4-AP at a 1Hz driving rate, 5 pM of 4-AP induced consequent 
restitutional APD lengthening. The restitution of the height of the action potential plateau was 
influenced by 4-AP in a similar way in each groups. Throughout the entire Dl range, the 
plateau occurred at higher membrane potentials in the presence of 5pM 4-AP. ( Fig 16 ) 
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FIGURE 16 
The effect of 4-AP on the action potential restitution at a 1 Hz basic cycle length in 
human right atrial trabeculae taken form patients with sinus-rhythm (SR) and chronic 
atrial fibrillation (AF) 
In sinus-rhythm preparations, the plateau restitution markedly followed a biphasic Dl-
dependence reaching the highest ( more depolarized ) plateau levels at Dis between 200 
and 600 ms. At Dis longer than 1000 ms, the action potential plateau ( and also the action 
potential dome ) became gradually smaller ( or less expressed ). This tedency, though, was 
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less noticeable in "fibrillating" preparations or in the carbachol pretreated sinus-rhythm group. 
The highest initial velocity of APD and plateau restitution was measured in "fibrillating" atrial 
preparations ( 4.39 ±1.21 msAPD/msDi and 1.46 ±0.32 mVpuvrEAu/msDi, respectively ). 
TABLE 5 
Parameters of the action potential restitution 
sinus rhythm ( n=11 ) 
parameter 
APD PLATEAU 
CONTROL +5 pM 4-AP CONTROL +5 pM 4-AP 
amplitudes 
A„ 302.7 ± 2.3 ms 278 ±4.1 ms ^ 54.05 ±0.21 mV 68.20 ±0.46 mV 
A, 119.0 ± 12.7 ms 94.9 ±3.3 ms 23.03 ± 0.28 mV 29.56 ± 0.67 mV ^ 
A2 30.0 ± 11.6 ms 53.4 ±3.2 ms 0.0016 ± 0.0002 
mV/ms 
0.0022 ± 0.0004 
mV/ms 
time constants 
110.5 ± 12.1 ms 44.3 ± 3.4 ms ^ 96.81 ±3.34 ms 72.85 ± 4.55 ms ^ 
563.4 ±243.7 ms 946.8 ± 180.8 ms ND ND 
sinus rhythm +1 pM carbachol ( n=6 ) 
parameter 
APD PLATEAU 
CONTROL +5 pM 4AP CONTROL +5 pM 4AP 
amplitudes 
A„ 193.2 ± 1.0 ms 236.3 ±1.3 ms^ . 50.70 ±0.31 mV 60.96 ± 0.64 mV 
A, 68.4 ±2.4 ms 140.3 ±3.1 ms^ . 17.57 ±0.60 mV 34.42 ±0.98 mV 
A2 ND ND 0.0007 ± 0.00031 
mV/ms 
0.0005 ± 0.00056 
mV/ms 
time constants 
D 223.5 ±25.0 ms 97.1 ±7.6 ms^ . 33.95 ±3.1 ms 33.62 ±2.93 ms 
T2 ND ND ND ND 
atrial fibrillation ( n=6 ) 
parameter 
APD PLATEAU 
CONTROL +5 pM 4-AP CONTROL +5 pM 4-AP 
amplitudes 
A„ 229.2 ± 0.6 ms 264.6 ± 0.7 ms + 78.59 ± 0.27 mV 90.77 ± 0.33 mV + 
A, 90.1 ±4.4 ms 118.6 ±4.9 m s ^ 35.26 ±0.54 mV 43.15 ±0.71 m V ^ 
A2 54.9 ±3.3 ms 60.1 ±3.7 ms 0.0015 ± 0.00023 
mV/ms 
0.001010.00028 
mV/ms 
time constants 
20.5 ±2.6 ms 20.1 ±2.2 ms 24.03 ± 1.05 ms 18.33 ±0.91 m s ^ . 
T2 291.2 ±29.3 ms 287.9 ±29.1 ms ND ND 
Restitution was modelled by the following equations: APD: A,, - A,exp( -DM x,) - A2exp( -DI/t2 ), PLATEAU: A<, - A,exp( -DI/ 
T| ) - A2DI, where DI: is the length of the diastolic interval in ms, A„ would be the value of the action potential parameter at infinitely long 
DI, A, and A2 are maximum amplitudes of the restitutional processes with ri and r2 time constants. In case of the PLATEAU restitution the 
second term was rather linearily dependent on DI with an A2 slope. Statistical analysis: two sampled Student's t-test < 0.05; ND: not 
determined. 
The commencement of APD restitution took place at a markedly slower kinetics In sinus-
rhythm preparations (1.08 ±0.29 msAPD/msD|) and it occurred at the slowest rate when sinus 
rhythm preparations were pretreated with carbachol ( 0.31 ±0.11 msAPD/msD| ). In all three 
cases, the initial velocities of both APD and plateau restitutions were uniformly increased by 
the application of 5 pM of4-AP. ( Fig 16, TABLE 5 ). 
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Other observations on human atrial preparations with 4-aminopyridine 
The effects of drugs on frequency dependent or restitutional action potential alterations are 
frequently analyzed to elucidate antiarrhythmic actions. Since the human atrial preparations 
under our experimental circumstances proved to be extremely sensitive to any changes in 
stimulation frequency, the frequency dependent 4-AP effects could not really be investigated 
in practice. Human atrial trabeculae responded to stimulation protocols rutinely used for 
cardiac preparations of other types83,84'85,86- with the shortening of APD, disappearance of the 
action potential dome and depolarization of the resting mebrane potential. In this respect 
"sinus-rhythm" preparations tended to perish faster than those from patients with atrial 
fibrillation. With longer diastolic intervals, the APD in diseased preparations often showed 
anomalous restitution, and their APD values grew gradually shorter at extrastimulus coupling 
times over 1000 ms. Although, this could not be proved statistically because of the limited 
number of preparations, inclination to anomalous restitution seemed to correlate with the 
severity of the heart insufficiency (i.e. with worsening of the left ventricular ejection fraction). 
It was also noticed that resposiveness of human atrial preparation to other APD prolonging 
interventions were sometimes qualitatively different from those of animal preparations, and 
this difference may even be enhanced by various pathological conditions. 
The role of INa in shaping the cardiac action potential as revealed by the application 
of detaimium in experiments on canine cardiac preparations 
The most characteristic action of a large group of antiarrhythmic drugs is the inhibition of INa, 
which causes a decrease in the conduction velocity. During the action potential plateau 
phase, the INa window current flows and the intensity of this is an important factor in 
determining the APD values. The extent of APD changes brought about by the INa block 
varies among cardiac tissues of different types. It is less prominent in ventricular myocytes 
and most evident in Purkinje fibers, as was demonstrated with detajmium in canine cardiac 
preparations. In both ventricular myocardium and Purkinje fibers, 1pM detajmium significantly 
decreased the action potential amplitude and Vmax, without influencing the resting and 
maximum diastolic potentials. In ventricular muscle, the APD value was only slightly affected 
by the drug. However, in Purkinje fibers 1 pM detajmium induced marked APD shortening83. ( 
Fig 17, ANNEX I) 
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FIGURE 17 
The effect of lpM detajmium on cardiac action potentials in canine ventricular (A) and 
Purkinje (B) fibers at a cycle length of 1000 ms. Drug-induced changes in the Vmax are 
given as inserts on the right side of the figure 
The application of lidocain in concentrations below 6 pM did not significantly influence the 
shape of "healthy" human atrial action potentials at a steady-state driving rate of 1Hz. 
However, in the presence of 12 pM lidocain, the plateau potential moved to more negative 
levels (from -12.5 ±3.2 to -21.8 ±2.8 mV) APD90 was shortened (from 351.0 ±10.2 to 298 ±5.7 
ms) in 3 representative experiments ( Fig 18 ). 
Tedisamil ( 1pM ) was found to significantly increase APD90 in both atrial and ventricular 
myocardium. The resting potential and action potential amplitude were not altered by the 
drug. The lengthening of repolarization was more pronounced in the atrial muscle than in 
ventricular one ( 28.9 ± 3.3 vs. 13.3±5.2%, n=6, [p<0.05]). Furthermore, the drug-induced 
APD prolongation at 50% repolarization was found to be significant in atrial but not in 
ventricular preparations. In ventricular myocardium 1pM depressed Vmax by a small but 
significant degree. In atrial myocardium, however, the drug effects on Vmax did not prove to 
be significant87. ( Fig 19 ) 
Effects of lidocaine on the action potential duration of "healthy" human atrial 
preparations 
Effects of tedisamil on human atrial and ventricular action potentials 
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FIGURE 18 
Effect of lidocaine on "healthy" human right atrial action potentials at a steady-state 
driving rate of 1Hz 
VENTRICLE 
B ATRIA 
100 ms 
o CONTROL 
• TEDISAMIL 1 pM 
FIGURE 19 
Effect of 1 pM tedisamil on the action potential in human ventricular (A) and atrial (B) 
fiber at a steady-state driving rate of 1Hz 
Effects of tedisamil, quinidine and Sotalol in rabbit atrial muscle 
The effects of these three drugs on repolarization were similar: the APD of action potentials 
was prolonged by each of them. Out of these drugs, only quinidine reduced Vmax 85.( Fig 20, 
ANNEX II ). 
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FIGURE 20 
Effect of tedisamil, quinidine and sotalol on the action potential in rabbit atrial muscle 
with a stimulation rate of 1Hz 
DISCUSSION 
Within human heart, IKur is exclusively expressed in the atria. According to 
cardiologists, who argue for the application of channel specific agents as antiarrhythmics, the 
targeted treatment of atrial tachyarrhythmias could be achieved by selective inhibition of this 
current. Their view is tacitly based on practical observations with ventricular arrhythmias and 
also on a common dogma in cardiology. The clinical observations lead them to think, that 1) 
in ventricular tissue, agents prolonging APD are effective antiarrhythmics at a relatively low 
risk of proarhyrthmia, and 2) selective agents have side effects that are controllable and less 
diverse than the nonselective ones. The current dogma is that by blocking a repolarizing K+ 
current one will inevitably increase the length of an action potential. 
One such example is IKur which can be selectively blocked using 4-AP. In isolated 
myocytes EC50 values of 30-50 pM were found in patch clamp experiments. With lt0 ( the 
other 4-AP sensitive current expressed in cardiac tissues ) a detectable block can be 
achieved by applying 4-AP concentrations of 100 pM or above. Our findings here also 
confirmed the belief that low 4-AP concentrations effectively modify the shape of human 
atrial action potentials. In isolated tissue preparations, however, the action potential 
parameters most sensitive to 4-AP were found to be the notch and plateau voltages ( with 
EC50 13-16 pM in right atrial trabeculae from patients with sinus-rhythm ). In our experimental 
circumstances 4-AP - even when applied in concentrations as low as 5pM - could still induce 
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readily detectable plateau elevations both in "sinus-rhythm" and "fibrillating" trabeculae. The 
determination of EC5o values in trabeculae from subjects with chronic atrial fibrillation could 
not be carried out, owing to the variability of "fibrillating" action potential forms and the limited 
number of available preparations. However, 4-AP induced APD changes were found to be 
different in "sinus rhythm" and "atrial fibrillation". In "atrial fibrillation" with triangular action 
potential forms, 4-AP clearly lengthened the APD. In "sinus-rhythm" preparations, though, a 
4-AP-induced APD shortening was detected. 
As the action potential simulations made apparent, the 4-AP-induced APD shortening 
observed in undiseased (sinus-rhythm) preparations is a result of the close relationship 
between IKur, IK, IKS, ICaL, INaCaExand the [Ca2+]j transient. 
The plateau potential of the sinus-rhythm action potentials in our experiments were 
between -30 and -20 mV under control conditions. If the repolarizing "force" gets reduced 
because of a selective IKur block, the depolarizing effect of ICaL becomes more pronouced 
and the action potential plateau shifts into a more positive potential range. Plateau potentials 
above -20 mV, however, activate IK more effectively, and the resulting APD will be even 
shorter than it would have been with unblocked IKur. The extent of plateau elevation basically 
depends on the kinetic features of ICaL and on the existence of a voltage range, where ICaL 
does not fully switch off and there is a flow of the ICaL window current. When the conditions 
do not favour a proper window current (i.e. the action potential plateau is too short in 
duration, the plateau voltages are remotely located from the the window domain, action 
potential notch can not be formed, or too deep notch voltages rapidly ensue), IKur block-
induced APD shortening can not occur. 
When IKr was selectively blocked by E-4031 in sinus-rhythm preparations with low 
plateau levels, the lengthening of APD turned to be moderate. When 4-AP was applied in the 
presence of E-4031, the 4-AP induced plateau elevation failed to acivate the IK current and 
consequently the lengthening effect (i.e. K+ channel block) on APD prevailed. If the IKS was 
strong (as was postulated in the action potential model), absent IK functions could be 
substituted to some extent by the activation of IKS at plateau levels around 0 mV. However, 
IKS becomes activated slower than IK and the evolution of the maximum IKS current is 
delayed. Owing to the kinetics of the process, an enhanced IKS could keep APDs at their 
original lengths (i.e. at values before the inhibition of IKr or the application of 4-AP). This 
mechanism might be also the reason why in current clamp experiments on isolated "sinus-
rhythm" myocytes, APD chages were not found in the presence of low 4-AP concentrations. 
In "fibrillating" atrial trabeculae, the action potential plateau was elevated and APD 
was lengthened by applying 4-AP. But in chronic atrial fibrillation, lt0 and ICaL are 
downregulated. Data on changes in densities of other ionic currents are at present 
contradictory. It has been shown that the characteristics of intracellular Ca2+ handling are 
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influenced by chronic atrial fibrillation in such a way that the Ca2+ sequestering capacity of 
the sarcoplasmic reticulum becomes reduced. The absence of an lt0 current decelerates the 
rate of early action potential repolarization, which - in turn - inhibits the reactivation of ICaL. 
Diminution of the ICaL intensity due to down-regulation, the failure to be reactivated again 
and also a reduction of [Ca2+]i transient together result in a decreased INaCaEx flow in the 
inward direction. As a result, the APD shortens, the action potential form becomes triangular 
and mechanical activity disappears. If IKur is blocked in "fibrillating" atrial myocytes, the 
elevation of the action potential can not lead to surplus IKr or IKs activation and APD 
lengthens. 
The role of M2 receptor activation in the triggering of atrial rhythm disturbances is 
nowadays regarded as an established fact. Most effective compounds used in atrial 
fibrillation also possess IKAch blocking activity88. The activation of M2 receptors in atrial 
preparation accelerates the fast repolarization, moves the action potential plateau to more 
negative voltages, shortens the APD and hyperpolarizes the resting mebrane potential. If K^ 
is blocked APD prolongation will occur, so long as the secondarily induced plateau elevation 
remains small and incapable of activating more IKr. 
In subjects with a structural heart disease, the risk a sympathetically triggered or 
sustained atrial fibrillation is much higher than in other heart patients. At dominance of the 
sympathetic tone, intracellular level of cAMP is elevated, ICaL becomes more activated, the 
intensity of IKr remains constant or becomes reduced, IKS is activated and IK, may become 
activated in atrial myocytes. The value of the resting mebrane potential depends on to what 
extent different cAMP dependent background currents can be counterbalanced by an 
increase in IKi. If the mechanisms outlined above hold, the APD of "fibrillating'' action 
potentials of sympathetically mediated types should be prolonged by the inhibition of IK^. 
Cardiac excitation may be viewed as an electrical wave with a wave-front 
corresponding to the action potential upstroke (phase 0) and a "wave-back" corresponding to 
repolarization (phase 3). The wavelength is the distance between the wave-front and wave-
back and is equivalent to the product of APD and the conduction velocity (CV). Moe and his 
coworkers89 demonstrated that simulated cardiac tissue could support multiple reentrant 
wave-fronts meandering in complex patterns resembling fibrillation, so they proposed the 
multiple wavelet hypothesis for atrial fibrillation. This hypothesis was later elegantly validated 
in the experiments of Allessie et al90. In cardiac tissue the conduction time (CT) depends also 
on the wave-front curvature91. At a critical curvature, the source of depolarizing currents is 
too small to bring the resting tissue to its threshold level, and propagation fails (break). When 
a break occurs along a propagating wavefront a spiral wave takes shape92,93. Spiral waves 
are greatly prone to instability: the core around which the spiral arm rotates is not stationary 
but meanders through the tissue and they can break up to form multiple waves94,95, resulting 
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in appearance of polymorphic tachycardia or even fibrillation in both ventricular96,97,98 and 
atrial tissues90. 
In two-dimensional models of cardiac tissue, the models incorporate many automata 
with resting, excited and refractory states ( the bare essentials of a cardiac cell ). When 
sufficient "preexisting" electrophysiological inhomogenities are introduced into the "tissue", 
cardiac waves spontaneously break up into random reentry99. In Moe's simple model this 
was achieved by randomly introducing local differences in the APD to cells throughout the 
tissue. In Moe's model, the heterogeneity was static, and was maintained throughuout the 
whole simulation procedure. Dynamic heterogeneity is another mechanism that requires a 
preexisting heterogeneity of some kind to create the first wavebreak. After that, the 
wavebreak proceeds spontaneously on its own. This type of wavebreak is primarily 
determined by the electrical restitutional properties, i.e. the dependence of APD and CV 
values on the preceeding Dl, defined as the interval between repolarization and the next 
action potential. The APD and CV values are therefore key determinants of the wavebreak 
process. The steepness of APD restitution is also a critical parameter for spiral wave stability. 
When the slope of APD restitution exceeds a certain value, a small change in Dl is amplified 
into a large change in APD. This in turn creates a larger change in Dl for the next wave, and 
so on. The positive feedback causes small wavelength oscillations to progressively grow until 
Dl becomes too short for the wave to propagate, resulting in a wavebreak. In contrast, a flat 
APD restitution acts like an attenuator, allowing perturbations in the wave to heal rather than 
expand100. By reducing APD restitution steepness, spiral wave breakup can be prevented 
and spiral wave behavior can be progressively stabilized. This concept is termed as the 
restitution hypothesis101 and has now been validated in several experimental models102,103. A 
natural consequence of steep APD restitution is the APD alternants. When they occur in the 
ventriculi they are electrophysiologicaiiy manifested as T-wave alternants (a clinically 
established harbinger of arrhythmia vulnerability104). This alarming connection between the 
steepness of the restitution and the propensity for the occurrence of APD alternants can 
readily be seen when the restitution is measured with stimulation protocols which alternately 
vary Dl as was done in studies undertaken here. 
The action potential restitution was altered by 4-AP both in "sinus-rhythm" and 
"fibrillating" atrial trabeculae in a similar manner as to the way in which the action potential 
characteristics were altered by the drug at a steady-state stimulation rate of 1Hz. When 
compared to the control, the height of the plateau amplitude was found to be higher and the 
APD was shorter throughout the whole Dl range (in the presence of 4-AP) in "sinus rhythm" 
preparations. In trabeculae taken from patients with chronic atrial fibrillation, where the drug-
induced plateau elevation was accompanied by APD lengthenings at 1Hz, APD restitution 
was also delayed by the application of 4-AP (i.e. restitutional APD was always longer in the 
ji 
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presence of 4-AP than under control conditions ). Shortened restitutional APDs after M2 
receptor activation were subsequently lengthened by applying 4-AP at all DIs. Compared 
with "sinus rhythm" preparations, the initial steepness of APD restitution was always higher in 
"fibrillating" trabeculae. The enhanced initial steepness of APD restitution was also observed 
with monophasic action potential measurements in patients and is regarded as a malign 
factor in the generation of atrial fibrillation105. Irrespective of the type of preparation (i.e. 
sinus-rhythm or "fibrillating"), the initial steepness of APD restitution was always enhanced by 
adding 4-AP in our experiments. Taking into account this latter observation and the 4-AP-
induced changes in APD restitution, 4-AP might exert antiarrhythmic actions in atrial 
fibrillation and in stages with predominance of the parasympathetic tone, but its effects on 
the electrical activity of the "healthy" atrial myocardium should rather be regarded as 
proarrhythmic. The potential proarrhythmic feature of 4-AP is also supported by the 
observation that action potential forms both in "sinus-rhythm" and "atrial-fibrillation" 
preparations were brought into a more triangular configuration, in ventricular tissue with 
diverse cellular elements, drugs generating more triangular action potential forms also 
possess enhanced proarrhythmic capabilities10. 
The secondary effects of the 4-AP -induced IKur block on the intensity of iCaL and the 
[Ca2+]i transient may also be hazardous to patients in atrial fibrillation or in the prefibrillatory 
stages with an electrical remodelling in progress. It is generally accepted today that the 
disruption of [Ca 2 l homeostasis plays a crucial role in the initiation of electrical remodelling 
and thereby in the perpetuation of atrial fibrillation36,46. 
Ca2+ enters the atrial cells through voltage-, receptor- and "source"-operated 
channels. Then the Na+-Ca2+ exchanger and less importantly a sarcolemmal Ca2+ pump are 
responsible for its removal. The inward-flowing Ca2+ ions (Ca2+-induced Ca2+ release) and 
also the rapid depolarization in during the onset of the action potential (voltage-induced Ca2+ 
release) mobilize Ca2+ from intracellular stores. In ventricular cells the Ca2+-induced Ca2+ 
release is brought about by an interplay between the L-type Ca2+ channels and the 
ryanodine-receptors in the T-tubules. In atrial cells the T-tubular system is less developed 
and a significant portion of the sarcoplasmatic reticulum is not attached to the sarcolemma 
(corbular sarcoplasmic reticulum). This also means, that in atrial myocardium ryanodin 
receptors may operate independently of the L-type Ca2+ channels. The corbular sarcoplasmic 
reticulum contains other Ca2+ releasing receptors regulated by intracellular second 
messengers (i.e. inositol triphosphates, diacylglycerol, or nicotine-andenosine-nucleotides). 
Ca2+ ions released into the myoplasm are taken up by the sarcoplasmic reticulum via the 
reticular Ca2+ pump and by the mitochondria. In the sarcoplasmic reticulum Ca2+ is 
sequestered and stored by Ca2+ binding proteins. Previously these Ca2+ binding proteins 
were thought to play only a passive role. Today it seems that reticular Ca2+ binding proteins 
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possess a signalling role in gene transcriptions and in events leading to apoptosis. The 
primary role of Ca2+ entering the mitochondria is to regulate the rate of ATP production with 
ATP requirements of ion-pumps and mechanical activity. Excess Ca2+ in the mitochondria 
also leads to a release of apoptotic mediators into the myoplasm106. (Fig 21) 
V O C a C iCaL 
ICaT 
R O C a C ICaTTX INaCa, Gap 
Junctions 
contractile 
machinery 
AVm 
regulatory 
sites 
importer 
Permeability ( 
Transition V synthesis 
! Pore C r Y --- Buffers and Chaperons* 'S§ 
FIGURE 21 
Connection between intracellular Ca2+ homeostasis and remodelling and apoptosis in 
chronic atrial fibrillation 
The connection between changes in [Ca2+]i and the cell-cycle is well documented in 
the literature. In some cases [Ca2+]i elevations leading to cell proliferation are introduced by 
the upregulation of K+ channels. In neurons, the normal expression pattern of ion-channel 
genes requires rhythmically fluctuating low level intracellular Ca2+ concentrations. The 
increased stimulus frequency in atrial flutter and fibrillation39 means, for the cell, an increased 
burden of the Ca2+ load. Depending on the activation sequence of various Ca2+ signalling 
systems, both in the myoplasm and in the cell-organelles, response patterns ranging from 
altered protein expression to myocardial hybernation and apoptosis may emerge (Fig 22). It 
follows - from the central role of [Ca2+]i in the pathomechanism of atrial fibrillation - that 
antiarrhythmic drugs become less suitable for the treatment of atrial flutter or atrial fibrillation 
the more they elevate secondarily the intracellular Ca2+ concentration. It is worth noting, that 
for repolarization lengthening ( Class 3 ) drugs in ventricular arrhythmias, it was always 
positive argued that they did not reduce the contractile force or even were able to increase 
the inortopy. However, the atrial tissue is more sensitive than the ventricular and any 
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increase in the "fibrillating" [Ca2+]j tends to promote aggravation of the disease. This may also 
provide an explanation for the increasing ineffectiveness of antiarrhyrthmics over time in the 
treatment of chronic atrial fibrillation. It is worth mentioning that cardiac glycosides tend to 
worsen reverse remodelling107 while verapamil delays the structural remodelling of atrial 
myocytes in animal models108. 
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FIGURE 22 
The dependence of ion channel remodelling and apoptosis on electrical activity 
and the extent of the Ca2+-load in atrial myocytes 
As computer simulation revealed, the effects of 4-AP on IKur are inevitably followed by 
an increase in the [Ca2+]j transient. But this means that even though IKur blocking had some 
antifibrillatory benefits in chronic atrial fibrillation (APD was prolonged and action potential 
restitution was delayed by 4-AP in trabeculae taken from subjects with chronic atrial 
fibrillation), the accompanying increase in [Ca2+]i has a tendency to prevent the complete 
recovery of the diseased (remodelled ) fibrillatory state. 
Our results also highlight the rule that what Is true for the ventriculi (i.e. if a 
channel/current has a repolarizing function, an antiarrhythmic effect should be achieved via 
its inhibition) is not necessarily true for atrial tissues. As it has also been demonstrated in 
most of our atrial action potential simulations, in atrial myocytes the interplay between ionic 
currents and changes in the ionic composition of the intracellular millieau is very complex 
and pharmacological interventions may result in effects that a reductionistic 
cardiophysiological logic fails to predict or imagine beforehand. 
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Computer simulation is an important tool for investigating possible causal connections 
between channel and transporter functions in cardiac myocytes. In our study, the importance 
of IKr and IKS currents in the modulation of 4-AP-induced APD changes was revealed by 
action potential simulations. As was also experimentally demonstrated application of an IKur 
blocker with an IKr blocker in combination, can minimize the proarrhythmic action potential 
effects of the IKur block. With such a combination the IKur-block-induced APD shortening 
could effectively be halted or even a net APD lengthening could be achieved. On the other 
hand, in the therapeutical application of an IKur+iKr blocker combination, doses of the IKr 
blocker could also be reduced, which would also reduce the risk of unwanted side effects, 
first and foremost arrhythmias of the "torsade" type. 
LIMITATIONS OF THE MODEL 
Action potential models are frequently used in electrophysiology. The application of 
models is inevitable for the integrative interpretation of experimental results obtained under 
the extremely aphysiological circumstances of the patch-clamp technique. In the more 
physiological multicellular preparations ( due to the unrestricted physiological interplay 
between the elementary functions ) actions seen in patch-clamp experiments can not always 
be verified persuasively. A scientific interpretation of such discrepancies is practically 
impossible without using computer models. However, the accuracy of the models is basically 
dependent on the accuracy of the experimental data. In the present action potential model, 
published maximum conductance values for ionic currents were used. Some of these 
conductances had to be readjusted in order to get typical multicellular action potential forms 
for a steady-state stimulation rate of 1Hz. (APPENDIX, TABLE 7 ). The gating equations for 
INa and ICaL had to be re-formulated ( APPENDIX, TABLE 8 ) because the relevant 
formalism available in the literature at present cannot be regarded as sensible either from a 
physiological or a computational point of view. Our equations yielded exactly the same 
voltage dependencies for steady-state and time constant values of the relevant gating 
variables as if they had been calculated using the traditional mathematical expressions. 
In this respect it is worth noting, that most action potential models treat the channel 
gating as if it could be represented by some set of simple open-closed state transitions. The 
whole channel gating is of course, a rather more complicated process. Fifty years of voltage 
clamp studies on ionic channels have yielded a wealth of kinetic data and the need to 
interpret this enormous set of data has led to empirical models in which gating consists of 
charge translocation between a finite ( but large ) number of discrete, so-called Markovian109 
states110,111,112. This discrete-state Markov models operating with forward and backward rate 
constants on the analogy of chemical reactions113 have been very successful in reproducing 
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the time course of native channel currents, but they lack a physical interpretaion that is 
consistent with properties of large channel proteins114. If it is so, and our present views on 
elementary channel processes are only fictions, the application of the traditional formalism 
cannot be regarded as an imperative. 
In our model the same compartments for ion-movements were taken into account as 
those in the Luo-Rudy (LR) model78 ( APPENDIX, Fig 23 ). However, the LR-model was 
specifically intended for guinea pig ventricular cells. Readjusting of compartment sizes to suit 
the situation in human atrial tissue was prevented by a scarcity of relevant data. 
The compartment sizes and the kinetics of the ion movements through and between 
the different compartments (especially for Ca2+), however, may directly influence 
sarcolemmal channel functions. Without an accurate representation of the simulated 
intracellular Ca2* movements, a realistic human atrial action potential model can not be 
imagined. 
In our model, the intracellular Ca2* handling was modelled in the same way as that by 
Zeng et al77. Although Ca2+ handling of this type proved to be a good choice in our model, it 
cannot be regarded as to be perfect. It does not take into consideration reticular Ca2*-release 
channels except ryanodine receptors and does not include reticular Ca2* buffers beyond 
calsequestrin. Even this Ca2+ handling model regards the ryanodine receptors as passive 
Ca2+ -regulated pores without any rectification. None of the models having been published so 
far, took Na*, K* and CI' channels in the subcellular membranes into consideration. Effects of 
drugs on ionic channels in membranes of cell organelles may also influence Ca2* movements 
and thereby Ca2*-regulated sarcolemmal ionic channels too. Action potential models ignore 
mitochondria, though their role in the Ca2+ homeostasis is well known. 
In our model, direct regulation by [Ca2*]; was postulated only for ICaL, IKS and IKca. 
However, INa and most of the K* currents are also known to be influenced by intra or extra-
cellular Ca2* ions. 
Effects mediated by intracellular second messengers such as cAMP, cGMP, 
muscarinergic effects but the activation of IKAch were not taken into account here. 
The role of IKr in resting myocytes has probably been overestimated. Under 
experimental circumstances the blocking of this current did not cause APD to such an extent 
that was predicted by the model. The maximum conductance of IKs in the model is about 10 
times greater than the relevant values found in myocardial preparations. The rectifying 
properties of K* channels was regarded as merely a voltage dependent process, and a block 
by divalent cations or intracellular polyamines was not incorporated into the model. 
Performace of the model was not tested in simulations for APD restitution or 
frequency-dependence. Our goal here was to test and simulate effects at 1Hz. 
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SUMMARY 
Therapeutical Implications 
We have seen that by inhibition of the atrial specific IKur current, 
antiarrhythmic/antifibrillatory effects can be expected in "fibrillating" atrial myocytes and in 
"healthy" atrial tissue with overwhelming parasympathetic dominance. For a long-term 
therapeutical application, due to the secondarily induced changes in the [ C a 2 + ] j homeostasis, 
the effectiveness of IKur blockers however seems to be uncertain. 
Antiarrhythmic potency of IKur blockers may be enhanced by combination with IK, 
blockers. In "healthy" human atrial myocytes IKur blockers alter action potential parameters 
and also the action potential restitution with a rather proarrhythmic profile. Application of IKr 
blockers (dofetilide or sotalol) in combinations with IK^ blockers could reduce the possible 
enhancement of the risk to develop or to favour atrial fibrillation due to the shortening of the 
action potential duration and effective refractory period caused by the IKur block in sinus 
rhythm. A possible advantage of combining IK^ and IKr block over IKur block alone, seems to 
be that doses of IKr blockers could be reduced. 
Importance of action potential simulations 
Our results also highlight that the rule what is true for the ventriculi ( i.e. if some 
channel/current has a repolarizing function, via its inhibition an antiarrhythmic effect should 
be achieved ) is not necessarily true for atrial tissues. As it has also been proved by our atrial 
action potential simulations, in atrial myocytes the interplay between ionic currents and 
changes in ionic composition of the intracellular millieau is very complex and 
pharmacological interventions may result in effects unforeseen to a reductionistic 
cardiophysiological logic. 
Computer simulation is an important tool in discovering potentially existing 
relationships between channel and transporter functions in cardiac myocytes. In the present 
study, importance of IKr and IKS currents in modulation of 4-AP-induced APD alterations was 
revealed by action potential simulations at first. 
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APPENDIX 
FIGURE 23 
Schematic representation of currents, pumps and exchangers included in the model 
The model consists of 5 compartments: the bulk medium, cleft space, myoplasm and junctional and 
network sarcoplasmic reticulum ( JSR and NSR ). 
TABLE 6 
ABBREVIATIONS EMPLOYED IN THE MODEL 
in alphabetical order 
a or P: forward or backward rate constants in the model, otherwise pore 
forming or regulatory channel subunits 
A: change in the indexed parameter between two integration steps 
y: relative mebrane distance ( see equations for INaCaEx ) 
x: time constants 
At: length of the integration step 
a: probability of channel activation ( except INa ) 
b: probability of channel inactivation ( except INa ) 
bCa: Ca!* dependent inactivation 
CALM: calmoduline 
CICR: Ca2+-induced Ca2+ release 
CSEQ: calsequestrine 
E: Nemsf s potential 
f: function of the indexed variable 
fscaie: scaling factor ( see INaCaEx ) 
g: conductance 
IbCa* or 1 Bkg.Ca- background Ca~" current 
IbNa, or Iskg.Na* background Na* current 
ICaL: L-type Ca2* current 
ICaT: T-type Ca2" current 
la: background CI current 
If: pacemaker current ( not included in our model ) 
IK,: inward rectifier K* current 
IKACh: acetylcholine activated K+ current 
IKca: Ca2* activated K* current 
IKr: rapid component of the delayed rectifier K+ current 
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IK,: slow component of the delayed rectifier K+ current 
IK«,.: ultrarapid delayed rectifier K+ current 
INa: fast Na+ current 
INaCaEl: Na+-Ca2+ exchanger current 
INaKpmp: Na+-K+ pump current 
Ip: non selective plateau current ( not included in model) 
It0 or 1,0,: transient outward K* current 
It02: Ca2+ activated CI" current (not included in model) 
J: ion fluxes 
JSR: junctional SR 
Kd: dissociation constants 
kQlO: temperature coefficient 
k,at: saturation constant ( see INaCaEx) 
leak: Ca2+ leak from the network SR 
NSR: network SR 
on, off: synonyms for activation (on) and inactivation ( o f f ) 
over: overload 
RyR: ryanodine receptor 
SR: sarcoplasmic reticulum 
SRCapmp: SR Ca+ pump 
ss (in index ): steady-state 
Thr: threshold 
trans: simple ion transport via diffusion 
TROP: troponine 
Up: uptake 
Vm: membrane potential 
VOL: volume 
VOLR: volume ratio of the indexed compartments 
X: ion in general 
z: valence of an indexed ion 
TABLE 7 
CONSTANTS AND INITIAL PARAMETER VALUES 
Parameter 
R: gas constant 
T: temperature 
F: Faraday constant 
C,„: membrane capacitance 
ACap: capacitive mebrane area 
VOLcen: cell volume 
V O L ^ : volume of the myoplasm 
VOLSR volume of the sarcoplasmic reticulum (SR) 
VOLNSR: volume of the network SR 
VOLJSR: volume of the junctional SR 
VOLCier,: volume of the intercellular space 
ionic concentrations in the bulk medium 
[K*] 
[Na+] 
[Ca2+1 
[CI] 
ionic concentrations in the cleft space 
[K*lcieft or [K*]„ 
[Na+]cleft or [Na+]0 
[Ca2+]cleftor[Ca2+]0 
Value 
8.314 J/K/mol 
310 K 
964867 C/mmol 
1.000 pF/cm2 
1.53E-04 cm2 
3.80E-08 ml 
2.47E-08 ml 
3.80E-09 ml 
2.47E-09 ml 
1.33E-09 ml 
4.94E-09 ml 
4.50É+00 mM 
1.44E+02 mM 
1.31E+00 mM 
1.14E+02 mM 
4.50E+00 mM * ' 
1.44E+02 mM 
1.31E+00 mM 
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[Cl]c!e„ or [Cl]0 
ionic concentrations in the myoplasm 
[K+]cen or [K+]my0 
[Na+]h [Na+]«n or [Na+]my0 
[ C a 2 + | i , [ C a 2 + ] c e i i or [Ca2+]myo 
[crii, [Ci]cen or [cr]myo 
parameters for Ca2+ handling by the SR 
NSR [Ca2+] (at rest) 
NSR [Ca2+]max (maximum Ca2+ concentration in NSR) 
NSR Ca2+ uptake Kd (ie. SERCa or SRCaprap) 
NSR Ca2+ uptake maximum rate 
NSR Ca2+ transfer to JSR ( T ) 
NSR Ca2+ uptake rate (at rest) 
NSR Ca2+ leak rate ( at rest) 
NSR Ca2+ transfer rate (at rest) 
JSR [Ca2+] ( at rest) 
JSR Ca2+ overload rate constant ( x ) 
JSR Ca2+ time constant for CICR „on" in overload 
JSR Ca2+ time constant for CICR „off ' in overload 
JSR Ca2+ overload induced release ( at rest) 
JSR threshold of voltage induced Ca release 
JSR CICR rate konstant 
JSR CICR rate (at rest) 
TROPONIN [Ca2+] (at rest) 
TROPONIN [ C a 2 + ] r a a x 
TROPONIN Ca2+Kd • 
CALMODULIN [Ca2+] (a t rest) 
CALMODULIN [Ca2+]max 
CALMODULIN [Ca2+] Kd 
CALSEQUESTRIN [Ca2+] ( at rest) 
CALSEQUESTRIN [Ca2+]max 
CALSEQUESTRIN Ca2+Kd 
CALSEQUESTRIN Ca2+ overload threshold 
INa 
Smax 
m GATE ( at rest) 
h G A T E (at rest) 
j G A T E (at rest) 
ICaT 
Smax 
a G A T E (at rest) 
b G A T E (a t res t ) 
ICaL 
Smax 
a G A T E (at rest) 
b G A T E (at rest) 
Ca2+-iduced inactivation, Kd 
I.« 
8 max 
a GATE l at rest) 
b GATE (at rest) 
IK r 
Smax 
a GATE (at rest) 
1.14E+02 mM 
t: 
1.60E+02 mM * 
7.02E+00 mM 
2.88E-04 mM 
6.90E+00 mM 
• w.; 
8.12E-02 mM * 
3.00E+00 mM 
9.00E-03 mM 
1.00E-02 mM/ms 
1.80E+01 ms 
3.11E-04 mM/ms 
2.71E-04 mM/ms 
7.76E-05 mM/ms 
7.99E-02 mM 
2.00E+01 1/ms 
4.00E+00 ms 
3.00E+00 ms 
1.49E-29 mM/ms 
-2.00E+01 mV 
1.00E+01 1/ms 
7.06E-06 mM/ms 
8.85E-04 mM 
7.00E-03 mM 
2.00E-03 mM 
5.42E-03 mM 
5.00E-02 mM 
2.38E-03 mM 
2.33E-01 mM 
9.00E+00 mM 
3.00E+00 mM. 
8.75E+00 mM 
• •.•« r 
:s -••• • - •35'- .-pK 
••fjL"-!-: 
1.50E+01 mS/pF 
5.17E-04 
9.97E-01 
1.00E+00 
5.00E-02 mS/pF 
5.04E-02 
8.29E-01 
• :' •• ? - • •' 
1.00E-01 (SR) mS/pF 
or 5.0E-03 (AF) 
4.48E-06 
9.40E-01 
4.00E-04 mM 
1.60E-01 (SR) mS/pF 
or 1.0E-02 (AF) 
1.67E-02 
1.00E+00 
3.00E-02 (SR) mS/pF 
or 3.0E-03 (AF) 
1.97E-04 
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b GATE (at rest) 9.91E-01 
IKr 
Smax 5.00E-02 (SR) mS/pF 
or 5.0E-03 (AF) 
a GATE (at rest) 2.00E-04 
Kd for [K+]o( CLEFT) 5.40E+00 mM 
IK, F • : '. c 
Smax 6.00E-01 (SR) mS/pF 
Kd for [Ca2+]j 
or 2.0E-01 (AF) 
5.00E-04 mM 
a GATE (at rest) 2.13E-02 
IK, WJi'f 
i K l Smax 6.00E-02 mS/pF 
IKACh 'mmmm 
Smax 7.00E-04 mS/pF 
or 7.00E-02 
K+ permeability 8.00E-07 cm/s 
Kd for [Ca2+]J ( MYOPLASM J 4.00E-03 mM 
IKc •• :••!•• ••A," : • iJi?;. j 
Smax 8.00E-07 cm/s. 
Kd for [Ca2+]J 4.00E-03 mM 
Ifikg,Na 
r. • - i : £ i 
Smax 1.00E-04 mS/pF 
lBkg,Ca ' i / v L iirili"-
Smax 
¥ 
1.00E-06 mS/pF 
? • , . - p¥- - y . 
1Bkg,CI 
Smax 9.00E-03 mS/pF " 
INaCaEl 1' . 
Imax 1.50E+00 pA/pF 
Kd for [Na^OJCLEFT) 8.70E+01 mM 
Kd for [Ca2+]0 ( CLEFT > 1.30E+00 mM 
INaKpmp 
Imax 2.04E+00 pA/pF 
Kd for [Na+]J ( MYOPLASM ) 1.00E+01 mM 
Kd for [K+]o(CLEFT) 1.50E+00 mM 
CALCULATION OF THE MEMBRANE POTENTIAL 
The membrane potential was calculated by integrating of differential equation d( Vm 
)/dt = - (Iljon + Istim )/Cm. Numerical integration was carried out according to the modified 
Euler's method published by Rudy at al78. Depending on the estimated error, the length of 
the instantaneous time step varied between 0.001 and 10 ms. 
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TABLE 7 
CURRENT EQUATIONS 
total mebrane currents 
Z 'NO - 'NO + 'flfcy.No * 2 l u a C a E x + 3 'woXpmp 
Z'x = 'to + Vur +lKr + 'xs +IK1 ~2 ¡HaKpmp 
Z ' c o = ' c o r + ' c o t + ' i k y . C o - 3 • tuaCaEx 
Z ' c / - ' f l k j . C / 
intracellular ion concentrations except Ca2 
Af. =»0" 
z F VOLu 
Jm,X 
[XJi.new ~ íxh,e!d + Mnew 2m,X 
ion concentrations in the cleft-space 
[XJtxilk - [X] cleft 
rcleft 
Jcleft.X 
VOL 
VOIRAI = 
VOLcl.ft 
[XJdeft.new = [X]cleft,old + (2cleft,X ~ At new 2m,X ' 
Ca leak from network-SR 
2NSR,leak - IF ([Ca2* ]HSK < [Ca2* Jmyo)THEN 0 ELSE 2*7 iroco o r,tf l
Ca>' 1h'iR-[C°2' ln,yo 
'NSR,leak 
Ca2* uptake ( SERCa ) 
JNSR,Up " JNSR.Up^ax 
+
 KaCa.NSR,Up 
+ [Ca2*]MY0 
2 NSR.tr 
int raretlcular Ca flow 
lCa!*]NsR-tCa2*]jiR 
r NSR,trans 
Ca2* concentrât ion in network - SR 
new = fC" * JNSN + at <2NSR.Up • V0LRNSR ~ 2 NSRJeak " 2 NSR.trans) 
'aCR.n 
Ca2* -induced Ca2' release(CICR) 
, - IP (-3SmV <Vm) THEN taCK * At ELSE 0 
1 CICRo, 
, + exp<-!a<ÏZ±> 
acRofí '1-CKR„ 
1 CICRr.i -
1 • exp( I la 
JOCR = JCICR,n ( CICR^ CICRoff CICRnl ([Ca
2* ]JStl - [Ca2* J^) 
Ca2* overload - induced Ca2* release 
IF ([CaCSEQJ Thr <= [CaCSEQ.]) AND (50ms<tovtr) THEN 
'•over/tew ~ "» ^over/nax ~ ^ 
ELSE 
* over,new ~ * over + At, J overjnax : 
*over . OVER m =1-exp(--
OVER0„ = exp(-
r.cff 
2aver ' 2averti OVER^ OVERoff ([Ca2*]JSK - [Ca2*]myo) 
Ca concentration in the junctional SR ( JSR ) 
ten2* 7 -b* -.b2*4C [La JjSR.new ' ^ 
b = [CSEQ.]total ' [CaCSEQ.] - A^jjsr - [Co2*]JSK * KdCa¡CSEQ 
c - Xdc0|CS£Q ([CaCSEQl + A[Ca,JSR T[Ca2*]JSR) 
¿[CaJJSR = at ( 3 NSR.trans ~ JOCR ~ 2aver) 
1 [CaCSEQ] = [CSEQltou, ^ 
Í + - Ca.CSEQ 
Ca2* concentrât ion in the myoplasm 
,9bc-2b3 - 27- d, arccosf r ——; 
,r le, 2 r. ~— , 2 (b3 -3 c)3'2 , b2 [Ca z* ]myo ,nrw = j [b2 -3c- cos( ^ ) - --
A = Kd c a .TROP + KdCa,CALM 
b = [CALM ]tota, + [TROP ]total - [Ca 2* ]Cotal + A 
c = (KdCaCALM Kd ca.TROP ) - [Ca2* ]tata, A + [TROP ]tota, KdCaCALM + [CALM]total Kd Ca JR0P 
d = -[Ca2* ]totai KdCa CALM • KdCa TROP 
[CaTROP ] = [TROP ]total 
1 + 
Kd Ca.TROP 
[CaCALM ] = [CALM ]total m 
[Ca 2+ ]n 
1 
1 + Ca.CALM 
[Ca2*]myo 
[Ca 1 total = [CaTROP ] + [CaCALM ] + af Ca Jmyo + [Ca 2* ]myo 
dfCa ]myo = àt (Jm.Ca + f 2 HSR .leak ~ 2 NSR ,Up ) ' í íyo + (2 CICR + 2 OVER ) ' myo I 
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Na * Ca 1' exchanger 
Vm F [Na * ]i . V_ • F [Ca *' li **p(r ™ )(' - I3 -a»P((' -r)-Zr-> 2. . 
, , , RT la *T [C la 
'NaCoEx ~ ' HaCaEx .max " J seal« ' lHa0 " JCaa 1 + ksat ' **P(( 1 -/) 
fscale -200, fHCo = ' , fCa0 = ~ > 7=0.35, ks 
1 (
KdEx.Na0j3 ^ ^ Ex,Ca0 
[Na*]0 * (Ca 2* ]Q 
sarcolemma/ Na* -K* pump 
IHaKpmp = 'NaKpmpjnax fha Ik 
1 + 0.1245 EXP(-0. 1 RTm-> + 0.0052 EXPF- -J^T-J ° 
f"° = —K31 • f* J • a-'""<l%T>-' 
J+
 KdNaKNal2 , + K°H<,KJ(a 67.3 
[Na * li [K'h 
background currents 
'skj.No = SBk,2*> 
'flkj.Ca = Seki.Ca <Vm ~ECa) 
'skj.CT = Ssfcj.C/ Cm - E d ) 
Equations for INa in general and as 
they were restructured for the human atrial AP-simulations 
Lou-Rudy-equations m3 h i (vm ~ENa) Rcdrut-tured expressions 
, R T , ,[Na~]0t > 
' *„-*„-rx E»°-Z-Fln([Na4> " 
t r — 2043 
X = XJJ-fXjj-xj expf ; 
r X 
r / i V m < -40mV)then: 
h„ .0.135 exp(-V^~l 
4.40 
r, -0.137 a-
u 
ym - 79.23 ,„ 
1-expi-5 1 ti-3.32* 
3.22 ' Vm t.95 < 
i . 0 1212 9 5 0 5 Gating fixations of the sodium channel as they are given by the original IR-equations 
1 - exDf- and by the iNa-model used for the AP-simriations presetted 7.26 
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Equations for ICaL in general and 
as they were restructured for the human atrial AP-simulations 
I .uo-itii i iy-i'quations 
i ' ~ V- . 10 1* expf- " I 6.24 , vm - 10, 1-txp<- I 6 24 
-«is V".10 
20.57 
*" " V , . 52" 'vm -50, 1*txp( ™ ) ( . « x p f - -" ) 
0 . 0 2 0 . 0 . 0 1 9 7 " P M ™ j * y ) ' ) 
X = x„ — (Xa -x)exp< ) rx RehtriirtumJ expressions 
Ym * 77 , Vm - 57 1*"«UM>*""—it*-' 
rt -451.1* 
7* ic°"i' 
0.00035 
PM -P, zF 
Vm zF l^'h "P<\*F>-IS"1. 
XT ' 
0.00055 
'Mi 
KaL-ui a b bCa (9m-tu) 
and 
iCaLc* -Pco a b bCa, 
iCaLxg - Pa* a b bCa, 
iCaLx - Px a b bCa, 
and 
iCaLjozxi - iCaLcx -¡CaL*, * KaLx 
( twrtenianchc-.Nattcl 
as the LR-model. but 
ICXL-SCXL ° b Kd <Vm-tc.), 
F RT ln,'Cd!'l* . 
'cx P [CP1'], 
9 0.020 * 0.0197 txp(-( m*~ J2) 
29 .57 
T-type Ca2* current transient outward K* current 
IcaT = ScaT °2 b (Vm - ECa) 'tot ' Sltal "3 b(Vm-EK) 
_ 1 
za a 23.7* 6.1 -v 2S ' kQwfa 4- 0) 
Itexpf mu5 ) = M5 0.S5 
"Qto = . a=i 2.5 + 
55 \TVi0" -9.5 7 F' -59 7 17 
1 * exp( 1 
10.« 7 «55 • iFexp,*»*20-47) 
zp = IF (Vm<0) THEN 10 - 0.«75 • Vm ELSE 10 -17.54 
i > „ = ' 1 
M \J , /Lf) Z x s 
1*exPr"7{U) kvo(a + 0) 
5 6 1 
kpiO = 3> " = U ,419 f • P * ,«.53*exp<
y-*£lLL)- ^ 35.56*exp7'^) 
Uexpf^fl, 
ultrarapid delayed rectifier K* current 
I,a1 'Smax fvm °3 t> (Vm-Ex) 
10 Urn -11 V_ -15. 1 
kqiofa * P) I*expf'-PLZ11, 
Iz 1 n 065 R 065 
kd,o-3, a- -y ,0 vm-30 • vm .62 
expf m ) * expf ) 2.5* expf ) 
-8.5
 F -59 7 17 _ , 
"55= y ;ro " kpwfaTp) 
1*expf m ) , Ym~F58x *4* ,Ym Id'. 16 21* expf 2g , 
T-
,Ym->-99:43, 1+ expf ) 27.48 
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rapid component_ of the delayed rectifier K * current slow component of Jhe delayed rectifier K* current 
<Xr = 9xr fxo fvm " (V„-EK) 
f lK1' f ' fXo = , 5 . . tvm - v - 9 
' + 22.4 > 
1 
0.00138 (V-+14.2) „ 0.00061 (Vm +38.9) 
a* ¡7 - n , • Pm 
6.9 
"ss - v 
<x,-Sx, feco o2 (Vm-E„) 4 
fco. » Kdw. I + -
lCo**h 
1 
8q(0 (a + ß) 
kqto + " = 0.000040 (Vm-19.9) 
l-exp< ) -17.0 
0.000035 (Vm -19.9) 
"ss ' 1 + expf-^) 
inward rectifier K* current 
'*f =Ski V T.70 
1 + exp( m- ) 10.29 ' 
acetylcholine - activated K' current 
iKt'SKf ëî <0-3 + V 7+59 53 > ^ ~E*> 
'[ACh]' 17.18 
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